期刊文献+

银屑病患者皮损中巨噬细胞移动抑制因子、环氧化酶-2及血管内皮生长因子的表达及意义 被引量:2

Expression of MIF,COX-2 and VEGF in psoriatic lesions and its significance
下载PDF
导出
摘要 目的:探讨巨噬细胞移动抑制因子(macrophage migration inhibitory factor,MIF)、环氧化酶-2(cycloxygenase-2,COX-2)及血管内皮生长因子(vascular endothelial growth factor,VEGF)与进行期寻常性银屑病的关系。方法:采用免疫组化SP方法,分别检测30例进行期寻常性银屑病患者皮损组织及10例正常皮肤组织中MIF、COX-2及VEGF的表达,并进行相关分析。结果:30例进行期寻常性银屑病患者皮损中MIF的平均吸光度(MA)值为0.32+0.03,COX-2的平均A值为0.31±0.02,VEGF的平均A值为0.30±0.05,以上3个因子在进行期寻常性银屑病患者皮损组织中的表达水平均显著上调,与对照组相比差异均有系统学意义(P<0.05)。以上3种因子之间存在正相关关系,相关系数r值分别为0.82、0.81、0.78(P<0.05)。结论:进行期寻常性银屑病患者皮损中MIF、COX-2及VEGF表达水平明显改变,该3种因子可能在银屑病发病机制中起作用。 Objective: To investigate the expression of macrophage migration inhibitory factor (MIF), cyclooxygenase-2 (COX- 2) and vascular endothelial growth factor (VEGF) and the relationship between them and psoriasis. Methods: The biopsies were taken from the skin lesions of 30 patients with psoriasis vulgaris and 10 healthy persons. The expression and distribution of MIF, COX-2 and VEGF proteins were detected by immunohistochemical method. Results: The mean optical density (MOD) of MIF, COX-2 or VEGF in patients with psoriasis was 0.32±0.03, 0.31±0.02 and 0.30±0.05, respectively;the three factors in psoriasis were significantly increased, statistically different from that of healthy controls (P〈 0.05, all). There were significantly relationships between the expressions of MIF, COX-2 and VEGF. Conclusion: The results indicate that the levels of MIF, COX-2 and VEGF are significantly higher in the lesions of psoriasis, which may be involved in the pathogenesis of psoriasis.
出处 《临床皮肤科杂志》 CAS CSCD 北大核心 2012年第4期207-210,共4页 Journal of Clinical Dermatology
  • 相关文献

参考文献6

二级参考文献20

  • 1朱凡,郑敏,鲍彰.银屑病患者皮损中血管内皮生长因子受体的表达与血管增生的关系[J].中华皮肤科杂志,2003,36(7):365-367. 被引量:33
  • 2张锡宝,罗权,吴志华,陈绍谦.血管内皮生长因子及其受体在银屑病发病中的作用及意义[J].中华皮肤科杂志,2005,38(3):140-142. 被引量:30
  • 3Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med, 1994, 180: 1141-1146.
  • 4Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability,and angiogenesis. Am J Pathol, 1995, 146: 1029-1039.
  • 5Weider N. Current pathologic methods for measuring intratumoral microvessel density with breast carcinoma and other solid tumor.Breast Cancer Res Treat, 1995, 36: 169-175.
  • 6Decaussin M, Sartelet H, Robert C, et al. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R-1-Flt1 and VEGF-R-2-Flk1/KDR) in non-small-cell lung carcinomas(NSCLCs): correlation with angiogenesis and survival. J Pathol,1999, 188: 369-377.
  • 7Bhushan M, Mclaughlin B, Weiss JB, et al. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol, 1999, 141: 1054-1060.
  • 8DIAZ B V, LENOIR MC, LADOUX A, et al. Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids [J]. J Biol Chem,2000,275 ( 1 ) :642 - 650.
  • 9CALANDRA T, ROGER T. Macrophage migration inhibitoryfactor: a regulator of innate immunity [ J ]. Nat Rev Immunol,2003,3 ( 10 ) : 791 -800.
  • 10LENG L, METZ CN, FANG Y, et al. MIF signal transduction initiated by binding to CD74[J]. J Exp Med,2003,197(11) :1467 -1476.

共引文献34

同被引文献34

引证文献2

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部